Covered recipient · General Payments record
QUINN KIRK
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,692.58
- Reported across 177 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $354.53 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $78.63 | 3 |
| DEXCOM, INC. | $76.62 | 2 |
| GlaxoSmithKline, LLC. | $45.13 | 3 |
| Lilly USA, LLC | $32.52 | 2 |
| CeQur Corporation | $31.04 | 1 |
| PFIZER INC. | $22.11 | 1 |
| Abbott Laboratories | $20.27 | 1 |
| Phathom Pharmaceuticals, Inc. | $18.63 | 1 |
| Acerta Pharma LLC | $14.91 | 1 |
| Novo Nordisk AS | $14.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $20.27 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125051450 | CMS |
| ABBVIE INC. | $18.65 | 03/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104080374 | CMS |
| ABBVIE INC. | $25.46 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104080376 | CMS |
| ABBVIE INC. | $34.52 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104080378 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.91 | 10/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104342688 | CMS |
| CeQur Corporation | $31.04 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126845354 | CMS |
| Dexcom, Inc. | $31.26 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153328775 | CMS |
| Dexcom, Inc. | $45.36 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153328777 | CMS |
| GlaxoSmithKline, LLC. | $15.43 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116710791 | CMS |
| GlaxoSmithKline, LLC. | $14.51 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116121139 | CMS |
| GlaxoSmithKline, LLC. | $15.19 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116461182 | CMS |
| Lilly USA, LLC | $16.26 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135323165 | CMS |
| Lilly USA, LLC | $16.26 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135305537 | CMS |
| Novo Nordisk Inc | $14.67 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097342930 | CMS |
| PFIZER INC. | $22.11 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131273287 | CMS |
| Phathom Pharmaceuticals, Inc. | $18.63 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151082557 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.